Search

everythinglearnresearchcommunity

for

Search:↓

Breezula's development has stalled, leaving users disappointed. The conversation includes skepticism about its approval and effectiveness.

Several new hair loss treatments are in development, with Cosmo Breezula and Kintor KX826 being the furthest along, expected to be commercialized by 2027. Veradermics is the only treatment in pill form, while others like KX/GT/Breezula will be topical.

The user is concerned about starting finasteride due to ongoing body development and seeks alternatives to maintain hair until age 25. They are considering options other than finasteride for hair loss management.

Discouragement regarding Pyrilutamide, a drug in development for hair loss, and the potential side effects of Finasteride. People discussed anecdotal experiences with Pyrilutamide as well as suggestions to wait out Phase 3 trials before making any conclusions.

A US federal judge ruled that using patients' stem cells for medical treatments is not under FDA jurisdiction, potentially speeding up development of stem cell-based hair loss therapies. Some users are optimistic about increased research and development, while others express skepticism about the ruling's impact on safety and efficacy standards.

Pelage Pharmaceuticals received $120 million in Series B funding for hair loss treatment development. The conversation expresses excitement and anticipation for the release and effectiveness of the treatment.

PP405 is a medicine, and Google Ventures is funding its development based on evidence from each phase, unlike their investment in Juicero, which was a trend-based gamble. Investing in medicine is a calculated risk, not reliant on being "cool."

Pelage Pharmaceuticals' PP405, a new hair loss treatment, was recognized by Time Magazine as one of the best inventions of 2025. The conversation expresses optimism about the recognition of this in-development treatment.

Stemson Therapeutics will start human trials for hair cloning in late 2025-2026. Product development is complete, and they are preparing for production and clinical trials.

Pyrilutamide, a potential hair loss treatment that is currently in development and may be available soon; an androgen receptor degrader which is also being developed as a potential treatment for hair loss; and the comparison between Pyrilutamide, finasteride, minoxidil, and RU58841.

The post argues for teenage use of finasteride to prevent hair loss, citing minimal side effects and personal success. Replies criticize the advice, highlighting potential developmental risks and questioning the safety of finasteride for teenagers.

Finasteride may pose a risk during pregnancy, so using a condom is recommended if a partner is pregnant. It is advised to stop finasteride before trying to conceive due to potential effects on fetal development.

There is no permanent cure for hair loss; treatments like finasteride, minoxidil, and hair transplants require ongoing use and are not universally effective. Genetic complexity and financial incentives for ongoing treatments hinder the development of a definitive cure.

Dutasteride in semen is considered a very small risk for partners, and fertility typically improves after stopping the medication. It is recommended to stop Dutasteride 3-6 months before trying to conceive to avoid potential impacts on fertility and fetal development.

A new hair cloning breakthrough suggests a potential cure for hair loss, though skepticism remains about its availability and cost. Users discuss the possibility of unlimited hair grafts for transplants and express hope for future developments.

A 22-year-old is experiencing hair loss after transitioning from fem HRT to DIY testosterone therapy and is considering using Dutasteride while also taking Saw Palmetto. They are concerned about the impact on virilization and proper development.

The conversation is optimistic about future hair loss treatments, highlighting Veradermics, Breezula, and PP405 as promising options expected by 2027-2028. The user expresses hope that these developments will prevent future generations from experiencing the same struggles with hair loss.

ET-02 is seen as promising for addressing hair loss and graying, but PP405 is more advanced in development and has better publicity. Some users plan to use both treatments alongside minoxidil and dutasteride.

A 17-year-old is experiencing hair thinning and is using minoxidil, ketoconazole shampoo, saw palmetto, and pumpkin seed oil. They are considering starting finasteride but are concerned about its effects on development and are seeking advice on whether to proceed with finasteride or switch to oral minoxidil.

Breezula (clascoterone) is expected to be available by late 2026, showing good long-term results with minimal side effects. KX-826 (pyrilutamide) acts faster but is still in earlier development stages.

A 20-year-old is considering starting dutasteride or finasteride for hair loss, with concerns about potential side effects and development. Users shared experiences with both treatments, noting that finasteride is often the first step, while dutasteride may be more effective for some, and emphasized consulting a healthcare provider.

A 19-year-old is concerned that starting finasteride for early hair loss might affect future beard growth. They plan to use minoxidil and finasteride due to a family history of male pattern baldness but worry about the impact on facial hair development.

An 18-year-old is experiencing significant hair loss and is considering starting finasteride treatment but is concerned about its effects on puberty and development. They previously tried finasteride but stopped due to side effects and are seeking advice on when it's safe to resume.

Shiseido's S-DSC Hair Multiplication Treatment in Japan is available to foreigners but is expensive and not very effective. Despite past disappointments, there is hope for future treatments with more options in development beyond Minoxidil and Finasteride.

The conversation discusses the potential of PP405 as a hair loss treatment, with some users expressing skepticism and others hopeful about its development. There is also mention of other treatments like Minoxidil, Finasteride, and Pyrilutamide, with users debating the effectiveness and safety of self-experimentation versus waiting for clinical trial results.

Characters in film and TV often use treatments like minoxidil, finasteride, and Propecia for hair loss, sometimes humorously. Examples include George from "Seinfeld," Tobias from "Arrested Development," and characters from "Better Call Saul," "The Simpsons," and "Modern Family."

A 17-year-old is considering starting finasteride and minoxidil for hair loss, despite concerns about potential side effects and the impact on development. The user is advised to check if puberty is complete and to consider using only minoxidil until adulthood.

Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

HMI 115 is being discussed as a potential hair loss treatment, with skepticism due to past disappointments like cosmeRNA, brezula, and pyrilutamide. The user is questioning if they should be hopeful for new developments in the next six years.